Advisory OTCs? GSK Weighs Third Class Paradigm With Xenical In Mind
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline Consumer Healthcare is internally discussing the impact a third class of pharmacy-only drugs could have on the self-care market
You may also be interested in...
Xenical Rx-To-OTC Switch Filing Slated For 2005
GlaxoSmithKline will file for an Rx-to-OTC switch of Xenical (orlistat) a year earlier than expected
GSK on Xenical
GlaxoSmithKline Consumer Healthcare says it plans to apply for an Rx-to-OTC switch for obesity drug Xenical within the existing two-class system. There may be future switches where "special conditions of sale or sponsor obligations" could remedy concerns about broader OTC availability, GSK acknowledges, but the firm maintains it "has no reason to believe" at this time that Xenical would fall into such a category. GSK Consumer Healthcare Director of Corporate Development Roland Regnier recently reported that GSK is "internally studying" the economics of a "third class" of drugs, but said the firm has not taken a formal position (1"The Tan Sheet" Sept. 20, 2004, p. 24)...
Glaxo Claims OTC Switch Dominance With An Eye Toward Xenical In 2006
GlaxoSmithKline believes an OTC switch of the prescription weight-loss drug Xenical (orlistat) could have the same success as its nonprescription nicotine replacement therapy offerings